BioCentury
ARTICLE | Finance

Prima targets NASDAQ

Australian cancer immunotherapy play Prima BioMed seeks NASDAQ listing

June 6, 2011 7:00 AM UTC

Australia's Prima BioMed Ltd. (ASX:PRR) hopes to capitalize on the substantial interest in fellow cancer immunotherapy play Dendreon Corp. (NASDAQ:DNDN) by listing on NASDAQ.

CEO Martin Rogers said the company is awaiting clearance for the listing from the SEC. "A lot of sellside analysts can cover us then," he noted. "There are 24 analysts that cover Dendreon."...